

The present Information Disclosure Statement is being filed within three months of the filing date of this patent application or prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Director is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C., Deposit Account No. 50-0786/4300.007897.

This application is a continuation application of Serial No. 09/621,475, filed July 21, 2000 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/621,475.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

WILLIAMS, MORGAN & AMERSON
CUSTOMER NO. 23720

Date: December 9, 2003

Mark D. Moore, Ph.D.
Reg. No. 42,903
10333 Richmond, Suite 1100
Houston, Texas 77042
(713) 934-4084
(713) 934-7011

AGENT FOR APPLICANTS

Form PTO-1449 (modified)	Atty. Docket No. 4300.007897	Serial No. Unknown
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicants Sergei Zolotukhin, Barry J. Byrne and Nicholas Muzyczka	
	Filing Date: Concurrently Herewith	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Pages 1-3</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,139,941	8-18-92	Muzyczka <i>et al.</i>	435	172.3	
	A2	5,646,034	7-08-97	Leavitt <i>et al.</i>	435	325	
	A3	5,658,776	8-19-97	Flotte <i>et al.</i>	435	172.3	
	A4	5,681,731	10-28-97	Lebkowski <i>et al.</i>			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 93/24641	12-1993	PCT			
	B2	WO 96/39495	12-1996	PCT			
	B3	WO 97/08298	03-1997	PCT			
	B4	WO 98/00524	01-1998	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Anderson and Grinsted, "A new method for the purification of human motile spermatozoa applying density-gradient centrifugation: Polysucrose media compared to percoll media," <i>J. Assis. Reprod. Genet.</i> , 14:624-28, 1997.
	C2	Bartlett and Samulski, "Fluorescent viral vectors: A new technique for the pharmacological analysis of gene therapy," <i>Nature Med.</i> , 4:635-37, 1998.
	C3	Basi and Rebois, "Rate zonal sedimentation of proteins in one hour or less," <i>Anal. Biochem.</i> , 251:103-09, 1997.
	C4	Cartwright <i>et al.</i> , "Investigation of the role of lipids in the assembly of very low density lipoproteins in rabbit hepatocytes," <i>J. Lipid Res.</i> , 38:531-45, 1997.

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. 4300.007897	Serial No. Unknown
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants Sergei Zolotukhin, Barry J. Byrne and Nicholas Muzyczka	
		Filing Date: Concurrently Herewith	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Pages 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C5	Chiorini <i>et al.</i> , "High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors," <i>Hum. Gene Ther.</i> , 6:1531-41, 1995.
	C6	Clark <i>et al.</i> , "Cell lines for the production of recombinant Adeno-associated virus," <i>Hum. Gene Ther.</i> , 6:1329-41, 1995.
	C7	Clark <i>et al.</i> , "Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses," <i>Hum. Gene Ther.</i> , 10:1031-39, 1999.
	C8	Conway <i>et al.</i> , "Recombinant Adeno-associated virus Type 2 replication and packaging is entirely supported by a Herpes Simplex virus Type 1 amplicon expressing rep and cap," <i>J. Virol.</i> , 71:8780-89, 1997.
	C9	Dracopoli, "Current Protocols in Human Genetics," John Wiley & Sons, Inc., Vol. 10, pp. 12.1.1-12.1.24, 1994-1998.
	C10	Ferrari <i>et al.</i> , "New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors," <i>Nature Med.</i> , 3:1295-97, 1997.
	C11	Graham <i>et al.</i> , "A novel method for the rapid separation of plasma lipoproteins using self-generating gradients of iodixanol," <i>Atherosclerosis</i> , 124:125-35, 1996.
	C12	Grimm <i>et al.</i> , "Novel tools for production and purification of recombinant AAV vectors," <i>Hum. Gene Ther.</i> , 9:2745-60, 1998.
	C13	Hermans <i>et al.</i> , "Purification of Higher Titer Adeno-Associated Virus Vectors for Gene Delivery in the Brain," Graduate School for Neurosciences, Netherlands Institute for Brain Research, Amsterdam, the Netherlands.
	C14	Hermonat and Muzyczka, "Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells," <i>Proc. Natl. Acad. Sci. USA</i> , 81:6466-70, 1984.
	C15	Herold <i>et al.</i> , "Identification of structural features of heparin required for inhibition of Herpes Simplex virus Type 1 binding," <i>Virol.</i> , 206:1108-16, 1995.
	C16	Inoue and Russell, "Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors," <i>J Virol.</i> , 72:7024-31, 1998.

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. 4300.007897	Serial No. Unknown
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicants Sergei Zolotukhin, Barry J. Byrne and Nicholas Muzyczka	
		Filing Date: Concurrently Herewith	Group: Unknown
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Pages 1-3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C17	Klein, "Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors," <i>Exper. Neurol.</i> , 150:183-94, 1998.
	C18	Lewin <i>et al.</i> , "Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa," <i>Nat. Med.</i> , 4:967-71, 1998.
	C19	Li <i>et al.</i> , "Role for highly regulated rep gene expression in adeno-associated virus vector production," <i>J. Virol.</i> , 71:5236-43, 1997.
	C20	Maxwell <i>et al.</i> , "Improved production of recombinant AAV by transient transfection of NB324K cells using electroporation," <i>J. Virol. Methods</i> , 63:129-36, 1997.
	C21	Neyts <i>et al.</i> , "Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate," <i>Virology</i> , 189:48-58, 1992.
	C22	Peel, "Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters," <i>Gene Ther.</i> , 4:16-24, 1997.
	C23	Salvetti, "Factors influencing recombinant adeno-associated virus production," <i>Hum. Gene Ther.</i> , 9:695-706, 1998.
	C24	Sasagawa <i>et al.</i> , "Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast <i>Scizosaccharomyces pombe</i> ," <i>Virology</i> , 206:126-35, 1995.
	C25	Snyder <i>et al.</i> , "Production of recombinant adeno-associated viral vectors," In: <i>Current Protocols in Human Genetics</i> (eds. Dracopoli <i>et al.</i>), John Wiley, New York, 1996.
	C26	Summerford and Samulski, "Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions," <i>J. Virol.</i> , 72:1438-45, 1998.
	C27	Tamayose <i>et al.</i> , "A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus by using packaging cell lines and sulfonated cellulose column chromatography," <i>Hum. Gene Ther.</i> , 7:507-13, 1996.
	C28	van der Burg <i>et al.</i> , "No porcine islet loss during density gradient purification in a novel iodixanol in University of Wisconsin solution," <i>Transplant. Proc.</i> , 30:362-63, 1998.
	C29	Xiao <i>et al.</i> , "Production of high-titer recombinant adeno-associated virus vectors in the absence of helper Adenovirus," <i>J. Virol.</i> , 72:2224-32, 1998.
	C30	Zolotukhin <i>et al.</i> , "Recombinant Adeno-Associated Virus Purification Using Novel Methods Improved Infectious Titer and Yield," <i>Gene Therapy</i> , 6:973-85, 1999.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.